Sana Biotechnology, Inc. announced that In addition to the new manufacturing plant, the company announced it has strengthened the leadership team with the appointments of Snehal Patel to lead Sanas internal and external manufacturing and Julie Lepin to lead regulatory affairs. Have long viewed an internal manufacturing capability as core to long-term success in consistently making these complex medicines at the scale and cost needed to maximize impact, said Steve Harr, Sanas President and Chief Executive Officer. This new facility enables to continue to develop internal manufacturing with no anticipated impact to the timing of programs, and in a more cost-effective manner.

Importantly, continue to attract the strong talent needed to execute on this vision and pipeline more broadly. Am excited to welcome Snehal and Julie to Sana. Snehal Patel, Senior Vice President and Head of Manufacturing.

Prior to Sana, Snehal was the Global Head and Vice President for Cell Therapy Manufacturing at Bristol Myers Squibb. He led the growing global manufacturing network to produce Clinical and Commercial Cell Therapy Products, including two cell therapies recently commercially launched in 2021 by BMS. Prior to this role he served as Site Head for Cell Therapy Manufacturing in Bothell, Washington. Prior to BMS, Snehal worked at Genentech/Roche for 18 years, holding a variety of different roles with increasing responsibility, including Head of Global External Drug Product Manufacturing, Head of Drug Product Operations, and Head of Quality Operations.

Julie Lepin, Senior Vice President and Head of Regulatory, Safety, and Quality. Julie joined Sana from Amgen where she was Vice President, Regulatory Affairs for Oncology, leading the regulatory strategies for a diverse and extensive portfolio of clinical stage and marketed products. The most recent approval in her portfolio was Lumakras, the first KRASG12C targeting agent.

Prior to Amgen, Julie was Head of Regulatory at Juno Therapeutics, Head of Regulatory, Oncology at Merck, and Head of Regulatory, Intercontinental at Amgen. Her leadership and regulatory insights were instrumental in numerous product approvals including Neulasta, Kepivance, Vectibix, Prolia, Keytruda, and more.